Bicara Therapeutics Inc.

NasdaqGM:BCAX Stock Report

Market Cap: US$882.5m

Bicara Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Claire Mazumdar Clemon

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage5.80%
CEO tenure6yrs
CEO ownership0.6%
Management average tenure3yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout

Nov 25

We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate

Jul 15
We're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate

Bicara: Innovative Precision Tumor Targeting

Apr 19

We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth

Mar 13
We Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth

Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me

Feb 02

CEO Compensation Analysis

How has Claire Mazumdar Clemon's remuneration changed compared to Bicara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$122m

Jun 30 2025n/an/a

-US$103m

Mar 31 2025n/an/a

-US$92m

Dec 31 2024US$9mUS$518k

-US$68m

Sep 30 2024n/an/a

-US$59m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$5mUS$450k

-US$52m

Compensation vs Market: Claire's total compensation ($USD8.92M) is above average for companies of similar size in the US market ($USD3.49M).

Compensation vs Earnings: Claire's compensation has increased whilst the company is unprofitable.

CEO

Claire Mazumdar Clemon (36 yo)

6yrs
Tenure
US$8,918,523
Compensation

Dr. Claire Mazumdar Clemon, PhD, M.B.A., serves as Director of Noora Health and is Director at Relay Therapeutics, Inc. since June 09, 2025. She serves as Chief Executive Officer and Director of Bicara The...

Leadership Team

NamePositionTenureCompensationOwnership
Claire Mazumdar Clemon
CEO & Director6yrsUS$8.92m0.62%
$ 5.5m
Ryan Cohlhepp
President5.3yrsUS$4.47m0.39%
$ 3.4m
Ivan Hyep
Chief Financial Officer4.8yrsUS$3.60m0.27%
$ 2.3m
Lara Meisner
Chief Legal Officer & Corporate Secretary2.2yrsno datano data
Pauline Dufresne
Chief People Officerno datano datano data
Rachel Salazar
SVP of R&D Strategy and Operationsno datano datano data
Sathish Hasige
Senior VP and Head of Technical Operations & Supply Chain3yrsno datano data
David Raben
Chief Medical Officer2.5yrsno data0.10%
$ 890.7k
Angela Windt
VP & Head of Regulatory Affairs3yrsno datano data
Jeltje Schulten
Senior Vice President of Clinical & Medical Affairs1.8yrsno datano data
Jean-Paul Rodrique
Senior VP & Global Head of Quality Assuranceno datano datano data
Jenna Cohen
Chief Corporate Affairs Officerno datano datano data
3.0yrs
Average Tenure
48yo
Average Age

Experienced Management: BCAX's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Claire Mazumdar Clemon
CEO & Director6yrsUS$8.92m0.62%
$ 5.5m
Ryan Cohlhepp
President2yrsUS$4.47m0.39%
$ 3.4m
Michael Powell
Independent Chairman of the Board1.4yrsUS$456.88k0%
$ 0
Nils Lonberg
Non-Executive Independent Director6.8yrsUS$364.75k0.055%
$ 483.1k
Anders Hove
Board Observerno datano datano data
Kiran Mazumdar-Shaw
Independent Director7.1yrsUS$332.90k0.82%
$ 7.2m
Scott Robertson
Independent Director2.3yrsUS$364.34k0%
$ 0
Keten Patel
Board Observerno datano datano data
Kathryn Haviland
Independent Director2.3yrsUS$361.35k0.014%
$ 119.8k
Jonathan Edwards
Board Observerno datano datano data
Carolyn Ng
Non-Executive Independent Director2.1yrsno datano data
Jake Simson
Non Executive Independent Director2.8yrsUS$332.90k0%
$ 0
2.3yrs
Average Tenure
49yo
Average Age

Experienced Board: BCAX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 17:55
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bicara Therapeutics Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric SchmidtCantor Fitzgerald & Co.
Richard J. LawGoldman Sachs
Robert BurnsH.C. Wainwright & Co.